Healthpoint, Ltd. company was founded in 1992 and is based in Fort Worth, Texas. Healthpoint, Ltd. operates as a subsidiary of DFB Pharmaceuticals, Inc. Healthpoint, Ltd., a specialty pharmaceutical company, develops and markets pharmaceutical and medical products for the treatment of chronic wounds. It focuses on the prevention and treatment of diseased and traumatized skin and related soft tissue. The company provides tissue management products, which includes sterile enzymatic debriding ointment, extracellular matrix-based wound product, bacteriostatic dressing, ointment for perineal wounds, papain-urea debriding ointment, doxepin hydrocloride cream, moisturizing dermal wound cleanser, hydrogel wound dressing, odor eliminator, powder for superficial skin infections caused by yeast, and protectant for intact and injured skin, as well as healing, debriding, and deodorizing ointment. It also offers surgical products, such as brush-free scrubbing products, surgical scrubs, waterless scrubs, healthcare personnel handwash and rub, hand and body antiseptic, one-step prep solutions, and topical anesthetic sprays. The company serves healthcare market, which includes nurses, physicians, surgeons, nursing homes, home health agencies, and office-based practices. It distributes its products through drug wholesalers and medical/surgical distributors.

Eczacibasi Pharmaceutical and Industrial Investment (formerly Eczacibasi Pharmaceuticals Manufacturing) helps to keep the residents of Turkey healthy. The company provides a variety of pharmaceutical and health care products, including vitamins, diagnostic substances, and personal care items. Eczacibasi Pharmaceutical has interests in prescription drug marketing and manufacturing firms, as well as health care supply distribution firms. It also sells generic drugs through a partnership with Zentiva (part of Sanofi-Aventis). The firm's real estate division invests in commercial properties. Founded in 1952, Eczacibasi Pharmaceutical is a subsidiary of family owned Turkish industrial group Eczacibasi Holding.

Genencor manufactures genetically modified enzymes for the industrial, agricultural, and consumer products markets. Using its biotechnology know-how, the company discovers useful enzymes (naturally occurring protein catalysts) and develops them for mass production; the enzymes are used in myriad ways, including as additives in animal feed and detergents, as a method of converting starch into ethanol, and in the production of textiles and paper. Genencor International is a division of food ingredient company Danisco.

Cypress Bioscience, Inc. was founded in 1981 and is based in San Diego, California. Cypress Bioscience, Inc. provides therapeutics and personalized medicine services. The company focuses on addressing the needs of physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders, such as fibromyalgia and rheumatoid arthritis. It offers Savella, a dual-reuptake inhibitor that preferentially blocks the reuptake of norepinephrine for the management of fibromyalgia. The company provides personalized medicine services, which include tests that are validated analytically and clinically to provide physicians with actionable information to help manage their patients care, including predicting the likelihood of developing disease or optimizing therapy. Its personalized medicine services include Avise PG, a test that supports dose optimization and therapeutic decision making for patients taking methotrexate, a therapy for rheumatoid arthritis (RA); and Avise MCV, a test that aids in the diagnosis and prognosis of RA. The company has a license agreement with Pierre Fabre Medicament to develop and sell products with the compound milnacipran as an active ingredient for various indications in the United States and Canada; a collaboration agreement with Forest Laboratories, Inc. for the development and marketing of milnacipran; and a reformulation and new product agreement with Collegium Pharmaceutical, Inc.

Teva Pharmaceuticals USA is the leading generic pharmaceutical company, marketing products from a wide range of therapeutic areas including cardiovascular, anti-infective, CNS, anti-inflammatory, oncolytic, antidiabetic, analgesic, dermatology, respiratory, and women's healthcare. Dosage forms include tablets and capsules, injectables, creams, ointments, inhalants, solutions, and suspensions. Teva USA products are marketed to chains, wholesalers, distributors and government agencies, as well as in health systems and oncology settings. Teva USA has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry. The company's mission is to play a leading role in the transformation of the U.S. healthcare system through its pre-eminence in the development, manufacture and marketing of generic pharmaceuticals.

AlphaVax, Inc. company was founded in 1998 by Robert Johnston, Nancy Davis, and Jonathan Smith, AlphaVax's chief scientific officer. AlphaVax, Inc. company is developing new vaccines for cancers and infectious diseases such as HIV/AIDS, Ebola, influenza, and other viral maladies. AlphaVax relies on a proprietary alphavaccine system that genetically alters diseased cells and transforms them into a vaccine when they attempt to replicate. Its technology could be used to develop preventative vaccines and therapeutic vaccines. Its pipeline consists of early-stage candidates. AlphaVax receives funding through partnerships and grants.

Rosetta Genomics Ltd. was founded in 2000 and is based in Rehovot, Israel.Rosetta Genomics Ltd. develops microRNA-based diagnostic and therapeutic products in Israel. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA and are used in regulating protein production. The company develops microRNA-based diagnostic programs for various cancers, as well as for the identification of the origin of the primary tumor of metastases; for differentiating squamous from non squamous non-small cell lung cancer; and for differentiating mesothelioma from other carcinomas in the lung and pleura. The company also focuses on the development of minimally/non-invasive, blood or serum-based molecular diagnostics tests. In addition, it develops microRNA-based therapeutic products for the treatment of liver cancer and chronic infections. The company has a license and collaboration agreement with Prometheus Laboratories Inc. to license and sublicense certain rights related to the company's microRNA-based cancer diagnostic tests; and a testing and administrative services agreement with Teva Pharmaceutical Industries Ltd. to distribute these tests in Turkey and Israel.

Emisphere Technologies, Inc. company was founded in 1985. It was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. The company is headquartered in Cedar Knolls, New Jersey. Emisphere Technologies, Inc., a biopharmaceutical company, focuses on the delivery of therapeutic molecules and pharmaceutical compounds using its ‘eligen’ technology. The eligen technology could be applied to the oral route of administration, as well as the other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal, or transdermal. The company’s product pipeline includes Oral Salmon Calcitonin, which is in Phase III clinical trials for the treatment of osteoporosis and osteoarthritis; Oral Recombinant Parathyroid Hormone, which is in Phase I clinical trials for the treatment of osteoporosis; and Oral Heparin that is in Phase III clinical trials, as well as Oral Low Molecular Weight Heparin, which is in Phase I clinical trials for the treatment of cardiovascular diseases. Its products under development also comprise Oral Insulin, which is in Phase II clinical trials, as well as Oral Glucagon-Like Peptides, which is in Phase I clinical trials for the treatment of diabetes; Oral Recombinant Human Growth Hormone that is in Phase I clinical trials for the treatment of growth disorders; and Oral Acyclovir, an anti-viral compound that is in Phase I clinical trials. In addition, the company’s product pipeline consists of Oral PYY 3-36, which is in Phase I clinical trials for treating obesity; Oral Cromolyn Sodium that is in Phase I clinical trials for the treatment of asthma/allergies; and Oral Gallium, a preclinical stage product candidate, for oncology treatment. Emisphere Technologies has collaboration agreements with Novartis Pharma AG; Roche; and Genta, Inc.

Celldex Therapeutics, Inc. company, formerly known as AVANT Immunotherapeutics, Inc., was founded in 1983 and is headquartered in Needham, Massachusetts. Celldex Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of vaccines and targeted immunotherapeutics for the treatment of cancer, infectious, and inflammatory diseases. The company focuses on the use of tumor-specific targets and human monoclonal antibodies to precisely deliver therapeutic agents through targeted immunization approach. It also offers bacterial vector delivery technologies with manufacturing and preservation processes that offer the potential for a new generation of infectious disease vaccines.Celldex Company's products include Rotarix for the prevention of rotavirus infection; and two human food safety vaccines for reducing salmonella infection in chickens and eggs. Its product pipeline also consists of products in various stages of development, including CDX-110, which is undergoing evaluation in a Phase 2/3 clinical trial for the treatment of glioblastoma multiforme, an aggressive form of brain cancer; CDX-1307, a product based on its proprietary APC Targeting Technology, which is in two Phase 1 clinical trials for patients with advanced pancreatic, bladder, breast, and colon cancer; a TP10, a complement inhibitor for transplantation and other indications; and three candidates based on its oral, rapidly-protecting, single-dose, and temperature-stable vaccine technology, such as combination vaccines for travelers, the military, and health needs. AVANT Immunotherapeutics has collaborative agreements with GlaxoSmithKline for the development and commercialization of oral rotavirus vaccine; Pfizer, Inc. for discovery and development of vaccines to protect animals, and to develop CDX-110; and Select Vaccines Limited for the development of viral vaccines.

Nutraceutical International Corp. was founded in 1993 and is based in Park City, Utah. Nutraceutical International Corporation engages in the manufacture, marketing, distribution, and retail of branded nutritional supplements and other natural products in the United States and internationally. The company offers vitamins and minerals, herbs, specialty formulas, personal care products, homeopathics, functional foods, and other products in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, creams, sprays, powders, and whole herbs. It also publishes, prints, and markets a line of books and booklets to book distributors, national retail bookstores, and health and natural food stores; distributes branded products of certain third parties; and owns neighborhood natural food markets and health food stores. Nutraceutical International sells its products primarily to and through domestic health and natural food stores.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.